Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population
Prostate cancer is the second most common invasive cancer diagnosed among men worldwide, and the most common cancer diagnosed in developed regions of the world, with an estimated age-standardized rate of 63 cases per 100,000 person-years.
Molecular Tests May Aid Clinical Decision-Making and Reduce Healthcare Costs
Jun Tang, PhD, James Bailey, MD, MPH, Cyril Chang, PhD, Richard Faris, PhD, Song Hee Hong, PhD, Michael Levin, MD, Junling Wang, PhD
Multiple sclerosis (MS) is a chronic, debilitating disease that attacks the central nervous system. It is estimated that approximately 400,000 people are living with MS in the United States, and approximately 10,400 patients are newly diagnosed with the disease annually.
What Makes Specialty Pharmacy Care So Special?
Hospital and Health Plan Partnerships: The Affordable Care Act’s Impact on Promoting Health and Wellness
Michelle Vu, PharmD candidate, Annesha White, PharmD, PhD, Virginia P. Kelley, MBA, Jennifer Kuca Hopper, MS, Cathy Liu, PharmD candidate
The growing number of partnerships between hospitals, outpatient care providers, and academic medical centers has been attributed, at least in part, to the healthcare reform initiated by the Affordable Care Act (ACA), which rewards hospitals for improving patient health outcomes and reducing healthcare costs.
Measurable Clarity in Healthcare Is Needed So Those Who Use the System Could Achieve a State of Well-Being
S. Pinar Bilir, MS, Qiufei Ma, PhD, Zhongyun Zhao, PhD, Elizabeth Wehler, MPH, Julie Munakata, MS, Beth Barber, PhD
Malignant melanoma is the sixth most often diagnosed cancer in the US. With new treatment options, here is an examination of costs associated with treating adverse events with various therapies.
Reducing Adverse Events and Healthcare Resource Waste by Careful Selection of the Best Drug Therapy
Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain
Ancilla W. Fernandes, PhD, David M. Kern, PhD, Catherine Datto, MD, MS, Yen-Wen Chen, PhD, Charles McLeskey, MD, Ozgur Tunceli, PhD
Opioid-induced constipation can adversely affect patients’ quality of life. This study was designed to assess healthcare utilization and costs, including all-cause, constipation-related, and pain-related costs, for patients with versus those without opioid-induced constipation.
Can Improved Management of Opioid-Induced Constipation Mitigate the Associated Costs?
In 2014, the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C raised concerns among the employer community in the United States. The cost implications of these specialty drugs, based on the possibility of their widespread use in patients without advanced disease, had corporate executives hurriedly recalculating their healthcare budgets.
Although the medical and economic burden of heart failure in the United States is already substantial, it will likely grow as the population ages and life expectancy increases
Validating the Impact of Heart Failure Through the Law of Large Numbers
Chronic myelogenous leukemia (CML) is a hematologic cancer that occurs primarily in adults. Although CML can occur at any age, the median age at diagnosis is 64 years, and the incidence increases with age.
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
Page 2 of 11
Results 11 - 20 of 106
Results 11 - 20 of 106